e18090 Publication Only Proposal ofamolecular testing algorithm fordifferentiated thyroid cancer (DTC). MargheritaNannini,AndreaRepaci,AntonioDeLeo,ValentinaVicennati,ElisaGruppioni, AnnalisaAltimari,EricaSolaroli,ElisaLodiRizzini,FabioMonari,GabriellaSavastio,LuigiLovato, GiovanniTallini,MariaA.Pantaleo,DarioDeBiase;DivisionofOncology,IRCCSAziendaOspeda- liero-Universitaria diBologna,Bologna,Italy;DivisionofEndocrinology andDiabetesPreventionand Care,IRCCSAziendaOspedaliero-Universitaria DiBologna,Bologna,Italy;UniversityofBologna,Bolo- gna,Italy;MolecularandTransplantation PathologyLaboratoryS.Orsola-Malpighi Hospital,Bologna, Italy;MaggioreHospitalAUSLBologna,Bologna,Italy;RadiationOncology,IRCSSAziendaOspeda- liero-Universitaria diBologna,Bologna,Italy;RadiationOncology,IRCCSAziendaOspedaliero-Univer- sitariaofBologna,Bologna,Italy;RadiologyDepartment, IRCCSAziendaOspedaliero-Universitaria di BolognaPoliclinicoSOrsola-Malpighi, Bologna,Italy,Bologna,Italy;DepartmentofMedicine(Diparti- mentodiMedicinaSpecialistica, DiagnosticaeSperimentale), MolecularDiagnosticUnit,Azienda USLdiBologna,UniversityofBologna,SchoolofMedicine,Bologna,Italy;DepartmentofExperimen- tal,Diagnostic,andSpecialtyMedicine–DIMES,Sant’Orsola-Malpighi Hospital,UniversityofBolo- gna,Bologna,Italy;Department ofPharmacyandBiotechnology (Dipartimento diFarmaciae Biotecnologie), MolecularDiagnosticUnit,AziendaUSLdiBologna,UniversityofBologna,Bologna, Italy Background: Inthegrowingeraofprecisionmedicineandtumor-agnostic therapies,themoleculartest- ingofDTCisbecomingmandatorytooptimizediagnosticandtherapeutical strategies.Evenifthe mostfrequentoncogenicevents,occurringinamutuallyexclusivemanner,areBRAFV600E,followed byRAS,genefusionsmainlyoccurringinRET,NTRK1-3,andALKgeneshavebeenalsofound.In thisscenario,thedefinitionofamoleculartestingalgorithmtobeimplemented forclinicalpracticeis needed,inordertooptimizeresourcesandtimeforbetterclinicalpatientmanagement. Methods:Gene mutationsandgenefusionswereevaluatedonDNAandRNAextractedfromcytologicorhistologic samples.Mutationsweretestedusingalab-developed multi-genepanelabletoanalyzethehot-spot regionsof28genes(totalof343amplicons,21.77kb);genefusionsweretestedusingtheOncomine Focusassaypanel. Results:Molecularcharacterization wasperformedonatotalof63DTC(50papil- larythyroidcarcinoma-PTC,8–follicularthyroidcarcinoma-FTC,5–hurthlecellcarcinoma-HCC) bythetreatingclinicianfordiagnostic,prognosticorclinicalreasons.In27cases(42.8%)atleastone DNAmutationwasdetected,17cases(26.9%)werepositiveforgenefusionrearrangement, inonly2 cases(3.1%)bothDNAmutationsandgenerearrangements werefoundandintheremaining17 (26.9%)casesnoDNAmutationsorrearrangements weredetected.Amongmutated-subgroup, BRAF V600Emutationwasthemostcommon(14of63cases–22.2%),followedbyRASmut(9cases– 14.2%:4NRAS,3HRAS,and3KRAS),bothassingleeventin7and4casesrespectively. Substitu- tionsinTERTpromoterregionwasfoundin16cases(25.3%),ofwhich14assecondaryevent.Other mutationsinTP53(4cases–6.3%,ofwhich2assingleevent),PIK3CA(1case–1.5%),AKT1(1 case–1.5%),andRNF43(1case–1.5%)weredetected.Amongriarrangedsubgroup,RETfusions andNTRK1-3wasfoundin8casesrespectively (12.6%),whileALKfusionwasfound1case(1.5%). Theconcomitant mutationalandfusioneventsfoundin2caseswerethefollowing:1)HRASand PAX8/PPARG; 2)PIK3CA/TP53/TERT andRET/CCDC6. Conclusions: Asexpected,BRAFandRASmu- tationsrepresentthemostcommongeneticeventsinDTCandoccurinamutualexclusivemanner. However,inabout30%ofpatients,mostlyofyoungage,withpapillaryhistologyandlymphnodalin- volvement,aclinicallyactionablegenerearrangement hasbeenfound.Thus,weproposeatwo-step moleculartestingalgorithmwithafirst-leveltesttoidentifythemostcommonmutationsandasec- ond-leveltest,includinglesscommonmutationsandgenerearrangements, ifthegenesanalyzedwith thefirstleveltestarewild-type.Thesecond-level testmaybeperformedup-frontincaseswherethere areclinicopathologic featuressuggestiveoffusiongeneTCgeneorinclinicallyaggressiveunconven- tionalcasesforwhichmoleculartherapyisbeingconsidered. ResearchSponsor:None.HEADANDNECKCANCER ©2022byAmericanSocietyofClinicalOncology.Visitabstracts.asco.org andsearchbyabstractfordisclosureinformation. Downloaded from ascopubs.org by 141.44.122.163 on October 24, 2025 from 141.044.122.163 Copyright © 2025 American Society of Clinical Oncology. All rights reserved.